	US 11,925,684 B2
	Compositions comprising cross-species-specific antibodies and uses thereof
Roman Kischel, Munich (DE); Tobias Raum, Munich (DE); Bernd Schlereth, Munich (DE); Doris Rau, Munich (DE); Ronny Cierpka, Munich (DE); and Peter Kufer, Munich (DE)
Assigned to AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed by AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed on Aug. 29, 2018, as Appl. No. 16/116,293.
Application 16/116,293 is a continuation of application No. 13/567,672, filed on Aug. 6, 2012, abandoned.
Application 13/567,672 is a continuation of application No. 12/083,351, granted, now 8,236,308, previously published as PCT/EP2006/009782, filed on Oct. 10, 2006.
Claims priority of provisional application 60/724,781, filed on Oct. 11, 2005.
Prior Publication US 2019/0070290 A1, Mar. 7, 2019
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/39558 (2013.01) [A61K 45/06 (2013.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 16/40 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01)]

16 Claims

1. A bispecific single chain antibody comprising:

(i) a first binding domain which binds to primate CD3 comprising

CDR-L1 (SEQ ID NO: 118), CDR-L2 (SEQ ID NO: 117), and CDR-L3 (SEQ ID NO: 116) and CDR-H1 (SEQ ID NO: 115), CDR-H2 (SEQ ID NO: 114) and CDR-H3 (SEQ ID NO: 112) or (SEQ ID NO: 113),

wherein the first binding domain comprises a VH region comprising the amino acid sequence set forth in SEQ ID NO: 110 and/or a VL region comprising the amino acid sequence set forth in SEQ ID NO: 168; and

(ii) a second binding domain binding to a cell surface antigen.